These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31571513)

  • 1. Pathological assessment of the lymph node biopsies for lymphadenopathy in rheumatoid arthritis.
    Yamada C; Oguro E; Tsuji S; Kudo-Tanaka E; Teshigawara S; Ohshima S; Hashimoto J; Saeki Y; Horiuchi T; Iizuka N; Tomita Y; Hoshida Y
    Mod Rheumatol; 2020 Sep; 30(5):835-842. PubMed ID: 31571513
    [No Abstract]   [Full Text] [Related]  

  • 2. Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort.
    Shimizu Y; Nakajima A; Inoue E; Shidara K; Sugimoto N; Seto Y; Tanaka E; Momohara S; Taniguchi A; Yamanaka H
    Clin Rheumatol; 2017 Jun; 36(6):1237-1245. PubMed ID: 28455827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: A retrospective, multicenter, descriptive study.
    Takada H; Kaneko Y; Nakano K; Tanaka M; Fujii T; Saito K; Sugimoto N; Sasaki S; Saito S; Saito R; Kuramoto N; Harigai M; Suzuki Y
    Mod Rheumatol; 2022 Jan; 32(1):32-40. PubMed ID: 33705243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Soluble Interleukin-2 Receptor Is a Biomarker for Pneumocystis jirovecii Pneumonia among Patients with Rheumatoid Arthritis under Methotrexate Therapy.
    Sakamoto N; Hara S; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kakugawa T; Yamaguchi H; Obase Y; Kushima H; Ishii H; Noguchi S; Kido T; Kobayashi T; Soejima Y; Yoshioka S; Ishimatsu Y; Yatera K; Kadota JI; Mukae H
    Tohoku J Exp Med; 2019 Jul; 248(3):209-216. PubMed ID: 31366819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic lymphoproliferative disorders in patients with rheumatoid arthritis are associated with a better clinical outcome.
    Tsukui D; Kanda H; Shinozaki-Ushiku A; Tateishi S; Takeshima Y; Nagafuchi Y; Sasaki O; Iwasaki Y; Harada H; Shibuya M; Sumitomo S; Shoda H; Kubo K; Fujio K; Nakamura F; Kurokawa M; Fukayama M; Yamamoto K
    Mod Rheumatol; 2018 Jul; 28(4):621-625. PubMed ID: 29057700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
    Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
    J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders.
    Takanashi S; Nakazato T; Aisa Y; Ito C; Arakaki H; Osada Y; Hirano M; Mori T
    Ann Hematol; 2018 Sep; 97(9):1611-1618. PubMed ID: 29713747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate-related lymphoproliferative disorder of the lumbar spine origin presenting with severe low-back pain: case report.
    Kikuchi N; Uesugi M; Koda M; Shimizu T; Murakami K; Kono M; Tanaka H; Yamazaki M
    J Neurosurg Spine; 2018 Nov; 29(5):545-548. PubMed ID: 30168781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
    Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
    Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The aggressive clinical courses of Hodgkin lymphoma primarily diagnosed as methotrexate-induced non-specific lymphoproliferative disorder in patients with rheumatoid arthritis.
    Tokuhira M; Tabayashi T; Tanaka Y; Takahashi Y; Kimura Y; Tomikawa T; Anan-Nemoto T; Momose S; Higashi M; Okuyama A; Watanabe R; Amano K; Tamaru JI; Kizaki M
    J Clin Exp Hematop; 2017; 56(3):165-169. PubMed ID: 28331131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
    Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
    Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Three cases of methotrexate-associated lymphoproliferative disorder (MTX-LPD)].
    Ishida Y; Asahi A; Wada T; Kanai N; Kobayashi Y; Moriai S; Kishibe K; Harabuchi Y
    Nihon Jibiinkoka Gakkai Kaiho; 2008 Aug; 111(8):594-8. PubMed ID: 18788425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of p53 and Bak gene mutations in lymphoproliferative disorders developing in rheumatoid arthritis.
    Xu JX; Hoshida Y; Hongyo T; Sasaki T; Miyazato H; Tomita Y; Aozasa K
    J Cancer Res Clin Oncol; 2007 Feb; 133(2):125-33. PubMed ID: 16988840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients.
    Kameda T; Dobashi H; Miyatake N; Inoo M; Onishi I; Kurata N; Mitsunaka H; Kawakami K; Fukumoto T; Susaki K; Izumikawa M; Nakashima S; Shimada H; Takeuchi Y; Haba R; Mano S; Onishi H; Imataki O; Matsunaga T
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1302-9. PubMed ID: 24515570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate-associated lymphoproliferative disorder with multiple pulmonary nodules and bilateral cervical lymphadenopathy.
    Makihara S; Kariya S; Noujima-Harada M; Ohara N; Naito T; Matsumoto J; Noda Y; Okano M; Yoshino T; Nishizaki K
    Auris Nasus Larynx; 2019 Dec; 46(6):927-933. PubMed ID: 30739816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult T-cell Leukemia/Lymphoma as a Methotrexate-associated Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis.
    Takajo I; Umekita K; Ikei Y; Oshima K; Okayama A
    Intern Med; 2018 Jul; 57(14):2071-2075. PubMed ID: 29491299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of iatrogenic immunodeficiency-associated lymphoproliferative disease in a patient treated with methotrexate for rheumatoid arthritis for 9 consecutive years, which Showed natural remission after discontinuation of MTX therapy].
    Kaneko J; Gozu K; Aoyagi H; Matsui T; Yoshida T; Hasegawa K; Isogai J; Maejima S
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2454-6. PubMed ID: 24394142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate-associated orbital lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report.
    Kobayashi Y; Kimura K; Fujitsu Y; Shinkawa K; Muta H; Sonoda KH
    Jpn J Ophthalmol; 2016 May; 60(3):212-8. PubMed ID: 27018050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatoid Arthritis Complicated with Nasal Septum Perforation Due to Methotrexate-associated Lymphoproliferative Disorder.
    Sakaguchi R; Fujikawa K; Okamoto M; Matsuo E; Matsumoto K; Uchida T; Shin-Ya K; Nakashima M; Mizokami A; Kawakami A
    Intern Med; 2019 Nov; 58(21):3167-3171. PubMed ID: 31292392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis.
    Yoshida Y; Takahashi Y; Yamashita H; Kano T; Kaneko H; Mimori A
    Mod Rheumatol; 2014 Sep; 24(5):763-5. PubMed ID: 24498893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.